Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Royalty Pharma PLC (RPRX : NSDQ)

• Company Description    Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $45.19 Daily Weekly Monthly 20 Day Moving Average: 4,001,129 shares Shares Outstanding: 577.24 (millions) Market Capitalization: $26,085.39 (millions) Beta: 0.42 52 Week High: $45.91 52 Week Low: $29.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.26% 16.00% 12 Week 16.11% 12.15% Year To Date 16.95% 17.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 East 59th Street - New York,NY 10022 USA ph: 212-883-0200 fax: - ir@royaltypharma.com http://www.royaltypharma.com

• General Corporate Information    Officers Pablo Legorreta - Chairman of the Board; Director & Chief Executive Terrance Coyne - Executive Vice President & Chief Financial Officer Bonnie Bassler - Director Errol De Souza - Director Catherine Engelbert - Director Peer Information Royalty Pharma PLC (CORR.) Royalty Pharma PLC (RSPI) Royalty Pharma PLC (CGXP) Royalty Pharma PLC (BGEN) Royalty Pharma PLC (GTBP) Royalty Pharma PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G7709Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 577.24 Most Recent Split Date: (:1) Beta: 0.42 Market Capitalization: $26,085.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.95% Current Fiscal Quarter EPS Consensus Estimate: $1.18 Indicated Annual Dividend: $0.88 Current Fiscal Year EPS Consensus Estimate: $5.01 Payout Ratio: 0.18 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.04 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: 9.02 Trailing 12 Months: 9.36 PEG Ratio: - Price Ratios Price/Book: 2.69 Price/Cash Flow: 9.46 Price / Sales: 10.97 EPS Growth vs. Year Ago Period: 26.96% vs. Previous Quarter: 24.79% Sales Growth vs. Year Ago Period: 4.71% vs. Previous Quarter: 2.13% ROE 12/31/25 - 28.21 09/30/25 - 26.36 06/30/25 - 25.54 ROA 12/31/25 - 14.55 09/30/25 - 14.08 06/30/25 - 14.11 Current Ratio 12/31/25 - 2.40 09/30/25 - 3.48 06/30/25 - 1.26 Quick Ratio 12/31/25 - 2.40 09/30/25 - 3.48 06/30/25 - 1.26 Operating Margin 12/31/25 - 114.55 09/30/25 - 110.08 06/30/25 - 110.45 Net Margin 12/31/25 - 32.38 09/30/25 - 32.51 06/30/25 - 44.23 Pre-Tax Margin 12/31/25 - 55.68 09/30/25 - 55.43 06/30/25 - 72.19 Book Value 12/31/25 - 16.83 09/30/25 - 16.62 06/30/25 - 16.30 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.88 09/30/25 - 0.89 06/30/25 - 0.74 Debt-to-Capital 12/31/25 - 46.87 09/30/25 - 47.10 06/30/25 - 42.43

Powered by Zacks Investment Research ©